Trial · NCT07900763
A TwiCs Study of TCM Management Based on Cardiopulmonary Screening in COPD
NCT07900763, Not applicable, Not yet recruiting, Henan University of Traditional Chinese Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A TwiCs Study of TCM Management Based on Cardiopulmonary Screening in COPD. Trials, record NCT07900763. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A TwiCs Study of TCM Management Based on Cardiopulmonary Screening in COPD
- NCT number
- NCT07900763
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Henan University of Traditional Chinese Medicine
- Conditions
- COPD With Coronary Artery Calcificatio
- Interventions
- TCM-Based Health Management Guided by Coronary Artery Calcium Scores
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants Developing Coronary Heart Disease | From randomization through Month 12 | |
| Secondary | Estimated 10-Year Cardiovascular Disease Risk Using the China-PAR Model | Baseline and Months 3，6, 9 and 12 | The estimated 10-year risk of cardiovascular disease will be calculated using the China-PAR risk assessment model. |
| Secondary | Coronary Artery Calcium Score Assessed Using the Agatston Method | Baseline and Months 12 | Coronary artery calcification will be quantified from chest CT images using the Agatston scoring method. |
| Secondary | Office Systolic Blood Pressure | Baseline and Months 3, 6, 9, and 12 | Office systolic blood pressure will be measured in millimeters of mercury according to the Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision). |
| Secondary | Office Diastolic Blood Pressure | Baseline and Months 3, 6, 9, and 12 | Office diastolic blood pressure will be measured in millimeters of mercury according to the Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision). |
| Secondary | Proportion of Participants Experiencing at Least One COPD Exacerbation | From randomization through Month 12; evaluated at Months 6, 12 | The proportion of participants experiencing at least one COPD exacerbation during follow-up. Two exacerbations occurring within an interval of 5 days will be counted as one exacerbation. |
| Secondary | Severity of COPD Exacerbations | From randomization through Month 12; evaluated at Months 6, and 12 | Each COPD exacerbation will be classified as mild, moderate, or severe. Mild exacerbations are worsening respiratory symptoms controlled by increased medication use. Moderate exacerbations require systemic corticosteroids and/or antibiotics. Severe exacerbations require hospitalization or emergency department treatment. |
| Secondary | Duration of COPD Exacerbations | From randomization through Month 12; evaluated at Months 6, 12 | The duration of each COPD exacerbation will be measured in days from the onset of exacerbation symptoms to clinical stabilization. |
| Secondary | Forced Vital Capacity | Baseline and Months 6 and 12 | Forced vital capacity will be measured by spirometry. |
| Secondary | Forced Expiratory Volume in 1 Second | Baseline and Months 6 and 12 | Forced expiratory volume in 1 second will be measured by spirometry. |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900763
GET https://conductscience.org/api/trials/v1/NCT07900763/registered?page=2